ยินดีต้อนรับกลับมา
เข้าร่วม CoinTime
เข้าสู่ระบบ email
สร้างบัญชี email
ตรวจสอบกล่องจดหมายของคุณ
Adicet Bio
About
Adicet Bio is a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer
- Redwood City,California,United States
- 101 - 250
- http://www.adicetbio.com
Details
- Last Funding Type
- Post-IPO Equity
- Industries
- Biopharma,Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2014
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Legal Name
- Adicet Bio, Inc.
Adicet Bio is a biotechnology company engaged in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 8, 2022 | Post-IPO Equity | — | — | — | — | Detail |
| Sep 2, 2019 | Series B | $80M | 7 | — | — | Detail |
| Jan 27, 2016 | Series A | $51M | 3 |
OrbiMed
|
— | Detail |
| Aug 26, 2015 | Series Unknown | $14.62M | — | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
Johnson & Johnson Innovation
|
— | Series B |
Novartis Venture Fund
|
— | Series B |
|
OrbiMed
|
— | Series B |
Pontifax
|
— | Series B |
Regeneron
|
— | Series B |
|
|
— | Series B |
Employee Profiles
Acquisition
Adicet Bio has acquired 1 organizations. Their most recent acquisition was Applied Immune Technologies on Jan 27, 2016. They acquired Applied Immune Technologies for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Jan 27, 2016
Applied Immune Technologies
|
Biotechnology | acquisition | — | Detail |
